NRXP
HEALTHCARENRX Pharmaceuticals Inc
AI Insight
What's Moving NRXP Today?
No stock-specific AI insight has been generated for NRXP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.62$5.05
$3.76
Fundamentals
Market Cap$165M
P/E Ratio—
EPS$-1.04
Dividend Yield—
Dividend / Share—
ROE-683.0%
Profit Margin—
Debt / Equity—
Trading
Volume800K
Avg Volume (10D)—
Shares Outstanding42.8M
NRXP News
26 articles- ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE TherapeuticsYahoo Finance·Jun 23, 2026
- NRx Pharmaceuticals Announces FDA Grant of Expanded AccessGlobeNewswire·Jun 22, 2026
- FDA lets NRx offer NRX-101 with TMS for severe depressionStock Titan·Jun 22, 2026
- NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of DepressionYahoo Finance·Jun 22, 2026
- NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Jun 17, 2026
- NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per ShareYahoo Finance·Jun 10, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.Yahoo Finance·Jun 5, 2026
- NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ OptionYahoo Finance·Jun 4, 2026
- NRx Pharmaceuticals Prices $20 Million Public Stock Offeringcitybiz·Jun 3, 2026
- NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockInvesting News Network·Jun 3, 2026
- NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's WhyBenzinga·Jun 3, 2026
- NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockYahoo Finance·Jun 2, 2026
- NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026Yahoo Finance·May 28, 2026
- NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemYahoo Finance·May 27, 2026
- Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street AnalystsYahoo Finance·May 24, 2026
- NRx Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 18, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 18, 2026
- NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 15, 2026
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateYahoo Finance·May 14, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and SuicidalityYahoo Finance·May 7, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free KetamineYahoo Finance·May 5, 2026
- New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO GlobalYahoo Finance·Apr 25, 2026
- NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine ProgramYahoo Finance·Apr 22, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and SuicidalityYahoo Finance·Apr 20, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial OfficerGlobeNewswire Inc.·Apr 13, 2026
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine ApplicationGlobeNewswire Inc.·Apr 6, 2026
All 26 articles loaded
Price Data
Open$3.80
Previous Close$3.76
Day High$3.93
Day Low$3.72
52 Week High$5.05
52 Week Low$1.62
52-Week Range
$1.62$5.05
$3.76
Fundamentals
Market Cap$165M
P/E Ratio—
EPS$-1.04
Dividend Yield—
Dividend / Share—
ROE-683.0%
Profit Margin—
Debt / Equity—
Trading
Volume800K
Avg Volume (10D)—
Shares Outstanding42.8M
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—